Enhancement of radiation therapy by the novel vascular targeting agent ZD6126

International Journal of Radiation Oncology Biology Physics

Volumn 53, Issue 1, 2002, Pages 164-171

  Siemann, Dietmar W ^a   Rojiani, Amyn M ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

KHT sarcoma; Vascular targeting; ZD6126

Indexed keywords

BIOASSAY; CELLS; DOSIMETRY; ONCOLOGY; RADIATION; TUMORS;

HISTOLOGIC EVALUATION;

RADIOTHERAPY;

ANTINEOPLASTIC AGENT; HOE 33342; N ACETYLCOCHINOL O PHOSPHATE; N ACETYLCOLCHINOL PHOSPHATE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CELL DAMAGE; CELL DEATH; CELL KILLING; CELL SUBPOPULATION; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DIFFUSION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SCREENING; DRUG TARGETING; FEMALE; HISTOLOGY; ISCHEMIA; LINEAR ACCELERATOR; MORPHOLOGY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; SARCOMA; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR GROWTH; TUMOR NECROSIS; VASCULAR TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; MICE; MICE, INBRED C3H; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; RADIOBIOLOGY; RADIOTHERAPY DOSAGE; SARCOMA, EXPERIMENTAL;

EID: 0036569804     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)02742-6     Document Type: Article

References (34)

1. Angiogenesis
2. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
3. Angiogenesis in the pathobiology and treatment of vascular and malignant diseases
4. Endothelial proliferation in tumors and normal tissue: Continuous labeling studies
5. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review
6. Microvascular corrosion casting in the study of tumor vascularity: A review
7. Angiogenesis as a target for tumor treatment
8. Vasculature as a target for tumour therapy
9. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy
10. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine. Evidence for a vascular mechanism
11. Anti-vascular approaches to solid tumor therapy: Evaluation of vinblastine and flavone acetic acid
12. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
13. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy
14. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
15. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
16. Targeting tumor blood vessels: An adjuvant strategy for radiation therapy
17. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues
18. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumours
19. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700
20. Interaction between combretastatin A4 disodium phosphate and radiation in murine tumours
21. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo
22. ZD6126: A new agent causing selective damage of tumor vasculature
23. Vascular targeting activity of ZD6126 in two tumour models growing in athymic rats
24. Radiobiological hypoxia in the KHT sarcoma: Predictions using the Eppendorf histograph
25. Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours
26. Area and volume measurements by random sampling methods
27. In vivo tumor response to single and multiple exposures of adriamycin
28. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi’s sarcoma
29. MRI evaluation of the effects of ZD6126 on tumor vasculature
30. Assessment of the novel tumor vascular targeting agent ZD6126 by non-invasive multi-gradient echo MRI
31. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
32. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma
33. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma